Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 4 records in total 4
    records per page




    Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis

    Authors: Hany Hasan Elsayed; Aly Sherif Hassaballa; Taha Aly Ahmed; Mohamed Gumaa; Hazem Youssef Sharkawy

    doi:10.21203/rs.3.rs-52224/v1 Date: 2020-08-01 Source: ResearchSquare

    Background: COVID 19 is the most recent cause of Adult respiratory distress syndrome MESHD Adult TRANS respiratory distress HP syndrome ARDS. Invasive mechanical ventilation IMV can support gas exchange in patients failing non-invasive ventilation, but its reported outcome is highly variable between countries. We conducted a systematic review and meta-analysis on IMV for COVID-associated ARDS to study its outcome among different countries.Methods: CENTRAL, MEDLINE/PubMed, Cochrane Library, and Scopus were systematically searched from June 8 2019 to June 8, 2020. Studies reporting five or more patients with end point outcome for severe COVID 19 infection MESHD treated with IMV were included. The main outcome assessed was mortality. Baseline, procedural, outcome, and validity data were systematically appraised and pooled with random-effect methods. Subgroup analysis for different countries was performed. Meta-regression for the effect of study timing and patient age TRANS and were tested. Publication bias was examined. This trial was registered with PROSPERO under registration number CRD42020190365Findings: Our electronic search retrieved 4770 citations, 103 of which were selected for full-text review. Twenty-one studies with a combined population of 37359 patients with COVID-19 fulfilled the inclusion criteria. From this population, 5800 patients were treated by invasive mechanical ventilation. Out of those, 3301 patients reached an endpoint of ICU discharge or death MESHD after invasive mechanical ventilation while the rest were still in the ICU. Mortality from IMV was highly variable among the included studies ranging between 21% and 100%. Random-effect pooled estimates suggested an overall in-hospital mortality risk ratio of 0.70 (95% confidence interval 0.608 to 0.797; I2 = 98%). Subgroup analysis according to country of origin showed homogeneity in the 8 Chinese studies with high pooled mortality risk ratio of 0.97 (I2 = 24%, p=0.23) (95% CI = 0.94-1.00), similar to Italy with a low pooled mortality risk ratio of 0.26 (95% CI 0.08-0.43) with homogeneity (p=0.86) while the later larger studies coming from the USA showed pooled estimate mortality risk ratio of 0.60 (95% CI 0.43-0.76) with persistent heterogeneity (I2 = 98%, p<0.001). Meta-regression showed that outcome from IMV improved with time (p<0.001). Age TRANS had no statistically significant effect on mortality (p= 0.102). Publication bias was excluded by visualizing the funnel plot of standard error, Egger's test with p=0.714 and Begg&Mazumdar test with p=0.334Interpretation: The study included the largest number of patients with outcome findings of IMV in this current pandemic. Our findings showed that the use of IMV for selected COVID 19 patients with severe ARDS carries a high mortality, but outcome has improved over the last few months and in more recent studies. The results should encourage physicians to use this facility when indicated for severely ill COVID-19 patients.

    Mechanical ventilation utilization in COVID-19: A systematic review and meta-analysis

    Authors: Mohammed A Almeshari; Nowaf Y Alobaidi; Mansour Al Asmri; Eyas Alhuthail; Ziyad Alshehri; Farhan Alenezi; Elizabeth Sapey; Dhruv Parekh

    doi:10.1101/2020.06.04.20122069 Date: 2020-06-05 Source: medRxiv

    Background: In December 2019, SARS-CoV-2 caused a global pandemic with a viral infection MESHD called COVID-19. The disease MESHD usually causes respiratory symptoms but in a small proportion of patients can lead to pneumonitis, Adult Respiratory Distress Syndrome MESHD Adult TRANS Respiratory Distress HP Syndrome and death MESHD. Invasive Mechanical Ventilation (IMV) is considered a life-saving treatment for COVID-19 patients and a huge demand for IMV devices was reported globally. This review aims to provide insight on the initial IMV practices for COVID-19 patients in the initial phase of the pandemic. Methods: Electronic databases (Embase and MEDLINE) were searched for applicable articles using relevant keywords. The references of included articles were hand searched. Articles that reported the use of IMV in adult TRANS COVID-19 patients were included in the review. The NIH quality assessment tool for cohort and cross-sectional studies was used to appraise studies. Results: 106 abstracts were identified from the databases search, of which 16 were included. 4 studies were included in the meta-analysis. In total, 9988 patients were included across all studies. The overall cases of COVID-19 requiring IMV ranged from 2-75%. Increased age TRANS and pre-existing comorbidities increased the likelihood of IMV requirement. The reported mortality rate in patients receiving IMV ranged between 50-100%. On average, IMV was required and initiated between 10-10.5 days from symptoms onset TRANS. When invasively ventilated, COVID-19 patients required IMV for a median of 10-17 days across studies. Little information was provided on ventilatory protocols or management strategies and was inconclusive. Conclusion: In these initial reporting studies for the first month of the pandemic, patients receiving IMV were older and had more pre-existing co-morbidities than those who did not require IMV. The mortality rate was high in COVID-19 patients who received IMV. Studies are needed to evaluate protocols and modalities of IMV to improve outcomes and identify the populations most likely to benefit from IMV.

    Kidney Diseases MESHD and COVID-19 Pandemic: A Review Article

    Authors: Tarek Abdelaziz

    id:10.20944/preprints202004.0289.v1 Date: 2020-04-16 Source: Preprints.org

    In December 2019, an animal human coronavirus transmission TRANS occurred in Wuhan, China. A state of global pandemic was shortly declared, among a very rapid contagious spread of the virus. The causative virus was identified as SARS CoV 2 virus and is genetically related to the previous SARS outbreak in 2003. The virus causes wide clinical spectrum from mild flu like symptoms to adult respiratory distress syndrome MESHD adult TRANS respiratory distress HP syndrome. Kidney involvement has been reported in several reports in patients with various degrees of severity of SARS CoV2 infection MESHD. As knowledge is evolving, the accurate incidence of AKI is not known. Many questions are yet to be answered as regards the effect of epidemiological variables and comorbidities on the occurrence of AKI. Some reports have observed the occurrence of hematuria MESHD hematuria HP and proteinuria MESHD proteinuria HP in a percentage of infected patients. Moreover, chronic kidney disease HP kidney disease MESHD has not been found in some reports to add to the adverse outcomes, an aspect that merits further exploration. Patients on regular hemodialysis may be vulnerable to contagion due to lower status of immunity and need for frequent attendance to healthcare facilities. Due to the previous factors, prevention and mitigation of SARS CoV2 virus in this vulnerable population constitutes a major challenge.

    Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China.

    Authors: Dawei Wang; Yimei Yin; Chang Hu; Xing Liu; Xingguo Zhang; Shuliang Zhou; Mingzhi Jian; Haibo Xu; John Prowle; Bo Hu; Yirong Li; Zhi-Yong Peng

    doi:10.21203/rs.3.rs-16485/v2 Date: 2020-03-04 Source: ResearchSquare

    Background In December 2019, Coronavirus Disease MESHD 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients. Methods Retrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan, and Xi-shui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic and clinical data were collected. Clinical course of survivors and non-survivors were compared. Risk factors for death MESHD were analyzed. Results A total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever MESHD fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP, lymphopenia MESHD lymphopenia HP and radiological multilobar pulmonary infiltrates HP. In severe cases, thrombocytopenia MESHD thrombocytopenia HP, acute kidney injury MESHD acute kidney injury HP, acute myocardial injury or adult respiratory distress syndrome MESHD adult TRANS respiratory distress HP syndrome were observed. During week 2, in mild cases, fever MESHD fever HP, cough MESHD cough HP and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia MESHD lymphopenia HP persisted. In severe cases, leukocytosis MESHD leukocytosis HP, neutrophilia HP and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia MESHD lymphopenia HP. However, severe cases showed persistent lymphopenia MESHD lymphopenia HP, severe acute respiratory dyspnea MESHD dyspnea HP syndrome MESHD , refractory shock MESHD shock HP, anuric acute kidney injury MESHD acute kidney injury HP, coagulopathy, thrombocytopenia MESHD thrombocytopenia HP and death MESHD. Older age TRANS and male TRANS sex were independent risk factors for poor outcome of the illness. Conclusions A period of 7–13 days after illness onset is the critical stage in COVID-19 course. Age TRANS and male TRANS gender TRANS were independent risk factors for death MESHD of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.